Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have earned an average rating of “Hold” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $12.00.
Several brokerages have commented on IRWD. Morgan Stanley decreased their price objective on shares of Ironwood Pharmaceuticals from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 15th. Northland Securities began coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, June 17th. They set an “outperform” rating and a $14.00 price objective for the company. Wells Fargo & Co decreased their price objective on shares of Ironwood Pharmaceuticals from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. BidaskClub cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 8th. Finally, ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 23rd.
IRWD stock opened at $9.17 on Tuesday. The firm has a 50 day moving average of $9.88 and a 200 day moving average of $10.73. The stock has a market capitalization of $1.46 billion, a PE ratio of 17.30 and a beta of 1.44. Ironwood Pharmaceuticals has a 52 week low of $7.91 and a 52 week high of $14.10.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 96.13% and a net margin of 19.14%. The company had revenue of $79.94 million during the quarter, compared to analyst estimates of $78.62 million. During the same quarter last year, the business earned ($0.26) earnings per share. The firm’s revenue for the quarter was up 16.3% on a year-over-year basis. Sell-side analysts anticipate that Ironwood Pharmaceuticals will post 0.4 earnings per share for the current year.
Large investors have recently bought and sold shares of the company. Strs Ohio purchased a new position in shares of Ironwood Pharmaceuticals during the 1st quarter valued at approximately $29,000. Amundi Pioneer Asset Management Inc. purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth $63,000. Diversified Trust Co purchased a new stake in Ironwood Pharmaceuticals in the 2nd quarter worth $115,000. Campbell & CO Investment Adviser LLC purchased a new stake in Ironwood Pharmaceuticals in the 2nd quarter worth $120,000. Finally, Balyasny Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth $129,000.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.